With the above-mentioned regulation of the SPRED1/NF1 interaction by CDK1 during the cell cycle in mind, a continuous inhibition of CDKs may work for short bouts of cancer therapy, but not long-term for the treatment of typically younger RASopathy patients. The gene discussed is NF1; the disease is RASopathy.